Joob Beuy, Wiwanitkit Viroj
Sanitation 1 Medical Academic Center Bangkok 101106, Thailand.
Dr DY Patil University Pune 410507, India.
Int J Physiol Pathophysiol Pharmacol. 2021 Oct 15;13(5):148-151. eCollection 2021.
The COVID-19 vaccine is a new vaccine aiming at control of COVID-19 pandemic. This new vaccine is useful for pandemic management, however, an important consideration is on its safety. Thrombosis is a problem might occur after COVID-19 vaccination and the increased blood viscosity is a pathomechanism. Here, the authors estimate on blood viscosity change after COVID-19 vaccination for vaccine recipient with underlying metabolic syndrome. Based on mathematical modelling and simulating technique, the authors estimate the change of blood viscosity after COVID-19 vaccination for persons with underlying metabolic syndrome. According to the estimation, blood viscosity in a healthy person is estimated 2.7 times higher than the normal value while blood viscosity in person with the underlying metabolic syndrome is estimated 2.99 times higher than the normal value. Based on this preliminary report, a more increased blood viscosity level is detected in vaccine recipients with the underlying metabolic syndrome. Monitoring of the blood viscosity problem among a vaccine recipient who has metabolic syndrome is recommended.
新冠疫苗是一种旨在控制新冠疫情大流行的新型疫苗。这种新型疫苗对疫情管理很有用,然而,一个重要的考虑因素是其安全性。血栓形成是新冠疫苗接种后可能出现的问题,血液粘度增加是其发病机制。在此,作者针对患有潜在代谢综合征的疫苗接种者,估计了新冠疫苗接种后的血液粘度变化。基于数学建模和模拟技术,作者估计了患有潜在代谢综合征的人接种新冠疫苗后的血液粘度变化。根据估计,健康人的血液粘度估计比正常值高2.7倍,而患有潜在代谢综合征的人的血液粘度估计比正常值高2.99倍。基于这份初步报告,在患有潜在代谢综合征的疫苗接种者中检测到血液粘度水平进一步升高。建议对患有代谢综合征的疫苗接种者的血液粘度问题进行监测。